Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.51 – $1.64
Volume6,522
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.93M
Price / earnings
—
Price / book
7.33×
Price / sales
6.96×
EV / sales
7.53×
EV / EBITDA
-0.22×
Profitability
Earnings per share
-$7.58
Return on assets
-285.15%
Return on equity
-3,559.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.62×
Current ratio
0.69×
Quick ratio
0.61×
Cash ratio
0.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NXL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$78.3K
$12.16K
$14.95K
$171.9K
$18.15K
$70.59K
$41.02K
$27.18K
Cost of revenue
$22.62K
$3.26K
$1.82K
$21.03K
$3.95K
$22.84K
$13.56K
$7.5K
Gross profit
$55.68K
$8.9K
$13.13K
$150.87K
$14.2K
$47.75K
$27.46K
$19.68K
Selling, general and administrative
$2.45M
$1.69M
$1.79M
$2.34M
$2.13M
$1.44M
$1.63M
$2.16M
Research and development
$219.83K
$564.48K
$346.38K
$224.94K
$226.52K
$225.77K
$406.29K
$737.24K
Total operating expenses
$2.66M
$2.26M
$2.13M
$2.56M
$2.36M
$1.67M
$2.04M
$2.9M
Operating income
-$2.61M
-$2.25M
-$2.12M
-$2.41M
-$2.35M
-$1.62M
-$2.01M
-$2.88M
Interest expense
-$52.77K
$129
$34
$8.24K
$2.29K
$4.69K
$1.1K
$3.19K
Income before taxes
-$2.66M
-$2.24M
-$2.1M
-$2.38M
-$2.28M
-$1.58M
-$1.99M
-$2.83M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.66M
-$2.24M
-$2.1M
-$2.38M
-$2.28M
-$1.58M
-$1.99M
-$2.84M
Net income attributable to common shareholders
-$2.66M
-$2.24M
-$2.1M
-$2.38M
-$2.28M
-$1.58M
-$1.99M
-$2.84M
EBITDA
-$2.57M
-$2.22M
-$2.11M
-$2.41M
-$2.34M
-$1.62M
-$2.01M
-$2.87M
Basic earnings per share
-$3.43
-$3.30
-$3.30
-$3.80
-$3.84
-$3.00
-$4.50
-$7.68
Diluted earnings per share
-$3.43
-$3.30
-$3.30
-$3.80
-$3.84
-$3.00
-$4.50
-$7.68
Recent news
Company coverage with links to the original publishers.
Nexalin Technology announced the issuance of U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia, providing intellectual property protection through 2042. The patent strengthens the company's competitive position in non-invasive deep-brain neurostimulation and supports its HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic strategy.
Nexalin announced a peer-reviewed study published in BMC Psychiatry demonstrating that its DIFS 77.5 Hz high-gamma neurostimulation technology produced statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents. The pilot study of six patients showed clinical improvements with measurable changes in brain-network activity, supporting the company's non-invasive neurostimulation platform. The findings add to Nexalin's growing body of evidence across multiple CNS indications including insomnia, depression, TBI, PTSD, Alzheimer's disease, and ADHD.
Nexalin Technology, a neurostimulation company, will participate in the 2025 Maxim Growth Summit, showcasing its non-invasive brain stimulation technology for mental health treatment.
Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, announced the closing of a $5.0 million public offering of its common stock.
Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 23, 2007
$9.375
Apr 16, 2007
recurring
Jan 3, 2007
$9.375
Jan 16, 2007
recurring
Sep 28, 2006
$9.375
Oct 16, 2006
recurring
Jun 29, 2006
$9.375
Jul 17, 2006
recurring
Mar 30, 2006
$9.375
Apr 17, 2006
recurring
Stock splits
Historical share-structure events and their execution dates.